The Role of HBP1 in Controlling Breast Cancer Dormancy Reawakening
Abstract
Breast cancer (BrCa) is the most common cancer affecting women worldwide. Yet even with tumor and lymph node removal, local radiation and systemic chemotherapy, roughly 22 percent (60,826 estimated cases in the U.S. in 2020) develop active bone metastases after a mean period of 8.4 years, correlating with severely decreased survival rates. Indeed, at least 50 percent of ductal carcinoma in situ cases showing no evidence of macroscopic metastatic disease nonetheless harbor disseminated metastatic cells. This indicates that bone metastatic growths are likely due to the reawakening of dormant BrCa cells that disseminated early to the bone. The molecular mechanisms regulating dormancy and reawakening remain poorly understood. One guiding principle, however, is that dormancy requires activation of p38MAPK and suppression of ERK1/2-MAPK, yet little is known regarding downstream p38 mediators.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1190799
Entities
People
- Irwin H Gelman
Organizations
- Health Research, Incorporated